Primary Progressive Multiple Sclerosis
GPTKB entity
Statements (43)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
multiple sclerosis subtype |
| gptkbp:abbreviation |
gptkb:PPMS
|
| gptkbp:affects |
central nervous system
|
| gptkbp:associatedWith |
demyelination
axonal loss |
| gptkbp:cause |
unknown
|
| gptkbp:diagnosedBy |
neurological examination
MRI lumbar puncture |
| gptkbp:diseaseCourse |
gradual worsening
|
| gptkbp:field |
neurology
|
| gptkbp:firstDescribed |
1916
|
| gptkbp:gender |
slightly more common in men than women
|
| gptkbp:hasNo |
cure
remission periods clear relapses |
| https://www.w3.org/2000/01/rdf-schema#label |
Primary Progressive Multiple Sclerosis
|
| gptkbp:ICD-10_code |
G35
|
| gptkbp:MeSH_ID |
D009103
|
| gptkbp:notableDifferenceFromRRMS |
no relapses
no remissions |
| gptkbp:OMIM |
126200
|
| gptkbp:onset |
typically after age 40
|
| gptkbp:progressionPattern |
steady progression
|
| gptkbp:proportionOfMSCases |
about 10-15%
|
| gptkbp:relatedTo |
gptkb:Relapsing-Remitting_Multiple_Sclerosis
Progressive-Relapsing Multiple Sclerosis Secondary Progressive Multiple Sclerosis |
| gptkbp:riskFactor |
age
genetics environmental factors |
| gptkbp:symptom |
balance problems
muscle weakness spasticity bladder dysfunction cognitive impairment walking difficulties |
| gptkbp:treatment |
gptkb:ocrelizumab
physical therapy symptomatic management |
| gptkbp:bfsParent |
gptkb:PPMS
|
| gptkbp:bfsLayer |
7
|